Medical Faculty
print

Links and Functions
Language Selection

Breadcrumb Navigation


Content

BMBF-Network ArthroMark

  • Coordinator: Prof. Hendrik Schulze-Koops
  • Affiliation:Center for Inflammatory Rheumatic Diseases (ERE)
  • Funding by BMBF: 2010 to 2019

Overall purpose of the project:
Rheumatic diseases are among the most common chronic inflammatory diseases. In addition to pronounced pain and progressive joint destruction, rheumatoid arthritis (RA), spondylarthritis (SpA) and psoriasis arthritis (PsA) reduce the ability to work, the quality of life and, if inadequately treated, life expectancy. Due to the therapeutic success achieved with biologics, there is a large variety of effective therapy options with individual advantages and safety aspects. However, in order to achieve optimal treatment success with patients, new tools are needed for early detection, more cost-effective but effective therapy, for new treatment strategies, for limited use of biologics, and for tailor-made therapy concepts for each patient individually. The main goal of the network is to identify new biomarkers and use modern imaging techniques for the diagnosis, follow-up and stratification of patients with RA, SpA and PsA. With the development of suitable biomarkers for these diseases, this project contributes to health research in the field of chronic diseases of the musculoskeletal system and aims to improve health care for common diseases. The network belongs to application-oriented research with close cooperation between research and care. Through the cooperation of different national centres, site-specific resources such as sample banks and clinical studies are to be made jointly usable and individual focal points in biomarker analysis are to be profitably networked. Joint data management and standardisation of data collection as well as the best possible characterisation of patients using new imaging methods should optimise the quality of marker testing. The results will be published in scientific journals. Treating physicians and patients will be informed about the new markers and their significance in corresponding clinical and lay-oriented information literature.

Source: ArthroMark